Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06951425 | An Exploratory Clinical Study of the Efficiency and Safety of TH027 in the Treatment of Relapsed/Refractory Solid Tumors | not yet recruiting | Early Phase 1 | 24 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06497010 | An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment | recruiting | Early Phase 1 | 40 | The Affiliated Hospital Of Guizhou Medical UniversityOTHER |
| 1 |
| May 1, 2025 |
| clinicaltrials |
| NCT05916248 | Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 34 | Ruijin HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06150365 | Personalized KSX01-TCRT in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06825455 | Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Peking UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06713148 | Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 42 | Fudan UniversityOTHER | 0 | Feb 6, 2025 | clinicaltrials |
| NCT06718946 | Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 38 | Fudan UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT05908773 | A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors | completed | Early Phase 1 | 1 | TransCode TherapeuticsINDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05346692 | Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer | completed | Early Phase 1 | 73 | Emory UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | terminated | Early Phase 1 | 95 | Five Prime Therapeutics, Inc.INDUSTRY | 2 | Nov 22, 2024 | clinicaltrials |
| NCT06697665 | An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours | recruiting | Early Phase 1 | 10 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06695689 | An Investigator-initiated Clinical Study of LM303 Injection for the Treatment of Advanced Solid Tumours | recruiting | Early Phase 1 | 10 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05141474 | Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors(NEXTGENTIL-ACT) | recruiting | Early Phase 1 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04742595 | Viral Specific T Cell Therapy for COVID-19 Related Pneumonia | completed | Early Phase 1 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06515626 | Genetically Modified T Cells Treating Malignant Tumors | recruiting | Early Phase 1 | 100 | Yi ZhangOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06613152 | HS-IT201 Injection in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 9 | Qingdao Sino-Cell Biomedicine Co., Ltd.INDUSTRY | 0 | Sep 25, 2024 | clinicaltrials |
| NCT05831033 | Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors | recruiting | Early Phase 1 | 16 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT05707325 | Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies(Reboot-101) | unknown | Early Phase 1 | 30 | Westlake TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05515692 | Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Jul 23, 2024 | clinicaltrials |
| NCT06431529 | A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors(Neoantigen-T) | unknown | Early Phase 1 | 6 | JIANG LONGWEIOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT05579275 | Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors | recruiting | Early Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06284226 | An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients(CCT-ANK-11) | withdrawn | Early Phase 1 | 0 | Beijing Kejing Biotechnology Co., Ltd.INDUSTRY | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06327997 | An Exploratory Study by Fast CAR T Cells | recruiting | Early Phase 1 | 20 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04294875 | Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies(MPT0B64) | withdrawn | Early Phase 1 | 0 | J Ints BioINDUSTRY | 0 | Mar 6, 2024 | clinicaltrials |
| NCT03905538 | Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors | withdrawn | Early Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04552418 | Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors | completed | Early Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06266923 | A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors. | completed | Early Phase 1 | 16 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06248697 | Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 16 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249256 | An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells | recruiting | Early Phase 1 | 12 | Shanghai Cell Therapy Group Co.,LtdINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03863145 | Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors | unknown | Early Phase 1 | 90 | Cosmo Technologies LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer | withdrawn | Early Phase 1 | 0 | Mainline Biosciences, Inc.INDUSTRY | 0 | Dec 21, 2023 | clinicaltrials |
| NCT05490264 | [68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors | unknown | Early Phase 1 | 20 | SmartNuclide BiopharmaINDUSTRY | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06126705 | 18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor | unknown | Early Phase 1 | 60 | Affiliated Hospital of North Sichuan Medical CollegeOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05728372 | 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT05971576 | A Clinical Study on TILs for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 2, 2023 | clinicaltrials |
| NCT05971589 | A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 5 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 2, 2023 | clinicaltrials |
| NCT05941936 | A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 5 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05828238 | Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05811975 | KSX01-TCRT Injection Project in Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05126927 | A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors | completed | Early Phase 1 | 11 | SmartNuclide BiopharmaINDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05539833 | KSH01-TCRT Solid Tumors(KSH01-TCRT) | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05580796 | KSH01-R02-101 Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05724732 | Exploratory Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Gynecologic Tumors | unknown | Early Phase 1 | 24 | RenJi HospitalOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05583201 | NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05649618 | TIL Cells for the Treatment of the Advanced Solid Tumors Patients | unknown | Early Phase 1 | 42 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 14, 2022 | clinicaltrials |
| NCT05648994 | TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors | unknown | Early Phase 1 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 13, 2022 | clinicaltrials |
Data updated 22 days agoSource updated May 13, 2025source: clinicaltrials